Search

Author

Subject

Date issued

Has File(s)

Search Results

Results 31-40 of 384 (Search time: 0.004 seconds).
    • Gender equity in anesthesia: is it time to rock the boat?
    Authors: M, Gisselbaek; OL Barreto, Chang; S, Saxena;  Advisor: -;  Co-Author: - (2023)

    While gender inequalities have been reduced over the last decades, the United Nations women’s report recently showed that women are still restricted from working in certain industries in almost 50% of countries (based on a sample from 93 countries) [1]. On top of that, essential women’s rights, like the right to abortion, have been withdrawn from the United States constitution [2, 3], obstructing the much-needed road to gender equity. Gender equity, which we are discussing here, is about giving everybody the tools to succeed regardless of gender [4].
    • How I prescribe prolonged intermittent renal replacement therapy
    Authors: Edward G., Clark; Anitha, Vijayan;  Advisor: -;  Co-Author: - (2023)

    Prolonged Intermittent Renal Replacement Therapy (PIRRT) is the term used to define ‘hybrid’ forms of renal replacement therapy. PIRRT can be provided using an intermittent hemodialysis machine or a continuous renal replacement therapy (CRRT) machine. Treatments are provided for a longer duration than typical intermittent hemodialysis treatments (6–12 h vs. 3–4 h, respectively) but not 24 h per day as is done for continuous renal replacement therapy (CRRT). Usually, PIRRT treatments are provided 4 to 7 times per week. PIRRT is a cost-effective and flexible modality with which to safely provide RRT for critically ill patients. We present a brief review on the use of PIRRT in the ICU with a focus on how we prescribe it in that setting.
    • Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
    Authors: Qian, Zhou; Zhong, Hu; Xin, Li;  Advisor: -;  Co-Author: - (2023)

    With the use of targeted drugs in lung cancer patients, targeted drug-induced interstitial lung disease (ILD) has attracted more and more attention. The incidence, time, and severity of different targeted drug-induced ILD vary. Almonertinib/HS-10296 is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Post-marketing safety and effectiveness of almonertinib have been confirmed. The reported adverse events of almonertinib were mainly an increase in creatine phosphokinase, aspartate aminotransferase, and alanine aminotransferase, and onset of rash. Almonertinib-induced ILD is rare.
    • The Minimum Effective Concentration (MEC95) of different volumes of ropivacaine for ultrasound-guided caudal epidural block: a dose-finding study
    Authors: Dongmei, Ma; Yan, Chen; Ping, Chen;  Advisor: -;  Co-Author: - (2023)

    Caudal epidural block (CEB) is a kind of epidural anesthesia in which local anesthesia is injected through the sacral hiatus into the sacral epidural space to block the sacral nerve and temporarily paralyze the area it controls [1]. CEB may be beneficial in anorectal surgery because its use may extend postoperative analgesia, which reduce the need for systemic analgesics and their potential side effects [2, 3]. Although CEB has many clinical applications, it is sometimes difficult to ascertain the anatomical location of the sacral hiatus and the caudal epidural space, particularly in adults [4, 5].